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Previously, we hypothesized that an RNA-based pathogenic pathway has a causal role in the
dominantly inherited unstable expanded repeat neurodegenerative diseases. In support of
this hypothesis we, and others, have characterized rCAG.rCUG100 repeat double-strand
RNA (dsRNA) as a previously unidentiﬁed agent capable of causing pathogenesis in a
Drosophila model of neurodegenerative disease. Dicer,Toll, and autophagy pathways have
distinct roles in this Drosophila dsRNA pathology. Dicer dependence is accompanied by
cleavage of rCAG.rCUG100 repeat dsRNA down to r(CAG)7 21-mers. Among the “molecular
hallmarks” of this pathway that have been identiﬁed in Drosophila, some [i.e., r(CAG)7
and elevated tumor necrosis factor] correlate with observations in affected people (e.g.,
Huntington’s disease and amyotrophic lateral sclerosis) or in related animal models (i.e.,
autophagy). TheToll pathway is activated in the presence of repeat-containing dsRNA and
toxicity is also dependent on this pathway. How might the endogenously expressed dsRNA
mediateToll -dependent toxicity in neuronal cells? Endogenous RNAs are normally shielded
fromToll pathway activation as part of the mechanism to distinguish “self” from “non-self”
RNAs. This typically involves post-transcriptional modiﬁcation of the RNA. Therefore, it is
likely that rCAG.rCUG100 repeat dsRNA has a characteristic property that interferes with
or evades this normal mechanism of shielding. We predict that repeat expansion leads
to an alteration in RNA structure and/or form that perturbs RNA modiﬁcation, causing
the unshielded repeat RNA (in the form of its Dicer -cleaved products) to be recognized
by Toll -like receptors (TLRs), with consequent activation of the Toll pathway leading to
loss of cell function and then ultimately cell death. We hypothesize that the proximal
cause of expanded repeat neurodegenerative diseases is theTLR recognition (and resultant
innate inﬂammatory response) of repeat RNA as “non-self” due to their paucity of “self”
modiﬁcation.
Keywords: RNA pathogenesis, Toll-like receptor, innate inflammation, expanded repeat diseases, neuro-
degeneration
INTRODUCTION
Since the ﬁrst discovery of trinucleotide repeat expansion as the
basis for many important human genetic diseases (Kremer et al.,
1991; La Spada et al., 1991; Yu et al., 1991; Richards and Suther-
land, 1992), there has been a vast amount of research in this
area (PubMed search“trinucleotide repeat disorders”gives>3,700
results). Much of this research is aimed at identifying the mech-
anism of pathogenesis underlying diseases caused by this form
of mutation. Individual diseases can follow either dominant or
recessive mode of inheritance indicating distinct pathogenic path-
ways. Repeat sequences that are expanded in copy number are
the basis for ∼20 dominantly inherited neurodegenerative dis-
eases, including Huntington’s disease (HD). Despite some of the
responsible genes being identiﬁed as long as 20 years ago, the iden-
tity and nature of the disease-causing pathogenic pathway remains
a gap in knowledge for these diseases, i.e., no deﬁnitive molecu-
lar pathway from the mutation to the clinical symptoms has yet
been identiﬁed. For at-risk individuals in families affected with
dominantly inherited late-onset neurodegenerative diseases due
to expanded repeats, the majority opt not to have the deﬁnitive
pre-symptomatic diagnostic test. Their preference is to live with
the uncertainty of not knowing, than the certainty of getting the
disease, as no treatments are yet available. Therefore, determin-
ing the pathogenic pathway and identifying therapeutic targets for
intervention is an urgent priority for reducing the impact of these
devastating diseases. This understanding is essential for rational
approaches to delay onset, slow progression, or ultimately effect
cure.
MOLECULAR PATHWAY FROM REPEAT EXPANSION TO
DISEASE
There are common properties exhibited by the various repeat
expansions that give rise to human disease. The vast majority
of these diseases originate from an existing repeat sequence that
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exhibits copy number variation in the human population. In each
case, the disease alleles arise when copy number increases beyond
a critical threshold. The repeat composition varies, but most are
trinucleotide repeats. In some diseases, the repeat expands to
the point where gene expression at the expanded repeat locus is
either substantially reduced or lost altogether, resulting in loss-
of-function of the repeat-harboring gene. Typically such diseases
are inherited in a recessive manner. Many repeat loci, however,
give rise to dominantly inherited diseases in a manner that is
not gene-dose dependent (i.e., two mutant alleles are no worse,
and may be even better than one – see Carroll et al., 2013). This
suggests that gain-of-function is the mechanism rather than hap-
loinsufﬁciency. Repeat copy number in many cases is a major
determinant of age at onset of clinical symptoms (referred to as
“anticipation”) indicating that the repeat itself is a rate-limiting
determinant of the pathogenic pathway. However, since pathology
typically involves cell death and there are many ways in which cells
die, identiﬁcation of the disease-causing “toxic agent” has been
problematic.
IS THERE A COMMON PATHOGENIC AGENT?
The unstable expanded repeat diseases (Figure 1) typically man-
ifest as neurodegenerative and/or muscular diseases, some with
a high degree of clinical overlap, despite affecting distinct pro-
teins and unrelated loci. Where expanded repeats are translated,
they generally code for polyglutamine; however, the proteins
in which they are located are all unrelated in the remainder
of their amino-acid sequence. Therefore, much attention has
been focused on expanded polyglutamine as the common basis
of pathology (McLeod et al., 2005; van Eyk et al., 2011, 2012).
Some of these diseases, however, have repeat expansions located
within untranslated RNAs and/or arise from repeat sequences
that cannot encode polyglutamine (Figure 1; Richards, 2001; La
Spada and Taylor, 2010). Despite these signiﬁcant differences in
the location of the repeat in this family of diseases they exhibit
overlapping symptoms resulting from neuronal loss of function
and/or neurodegeneration. In addition, in most cases the polyglu-
tamine and“untranslated”diseases have similar disease allele copy
number repeat thresholds (HD CAG > 36, SCA17 CAG > 47,
FXTAS CGG > 55, HDL2 CUG > 44, DM1 CUG > 50, SCA12
CAG> 66). This suggests that there may be a common pathogenic
agent or agents in the translated and untranslated repeat diseases.
RNA MAY BE PATHOGENIC IN TRANSLATED REPEAT
DISEASES
While there is growing consensus that RNA plays a causal role in
“non-coding repeat expansion disorders,” its contribution when
the repeat is located in coding regions (speciﬁcally polyglutamine
disorders) is more controversial (Fiszer and Krzyzosiak, 2013). Yet
even here there is evidence that RNA is key. For example, inter-
mediate copy number CAG alleles of SCA2 that are below the
threshold required to encode aggregate forming polyglutamine,
increase the risk of amyotrophic lateral sclerosis (ALS; Elden et al.,
2010). Furthermore, interruption of CAG repeat with CAA dra-
matically mitigates polyglutamine toxicity in a Drosophila model
of SCA3 (Li et al., 2008).
It is possible that multiple pathways (at least one of which
is RNA mediated) contribute to progression of expanded repeat
neurodegenerative diseases. In support of this possibility, ALS
and SCA7 both appear to involve two cell types (nerve cells
and glial cells; Furrer et al., 2011; Polymenidou and Cleveland,
2011). Astrocytes and glial cells have both been shown to affect
their neighboring neurons in individuals with repeat expan-
sions, leading Ilieva et al. (2009) to hypothesize that the onset
of the disease is determined in the nerve cell, and the progres-
sion of the disease determined in adjacent glial(-like) cells. But
FIGURE 1 | Location of expanded repeats in disease genes. SCA, spinocerebellar ataxia (multiple loci numbered); FXTAS, fragile X tremor ataxia syndrome;
ALS, amyotrophic lateral sclerosis; FTLD, frontotemporal lobar dementia; SBMA, spinobulbar muscular atrophy; DRPLA, dentatorubral-pallidoluysian atrophy.
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importantly, there is consistent evidence implicating RNA as of
principle importance as the originating causal event that initiates
pathology.
MECHANISMS OF RNA-INITIATED PATHOLOGY
What precedents and potential mechanisms are there for RNA to
initiate pathogenesis in human diseases? See Figure 2.
SINGLE-STRANDED RNA TOXICITY
Precedence for expanded repeat RNA being a disease-causing
entity in its own right ﬁrst came from the DM1 and DM2 repeat
expansions that both give rise to myotonic dystrophy (Ranum and
Day, 2004). The repeat expansions in these diseases are similar,
but importantly, not identical (CUG vs. CCUG) and are located in
untranslated regions (3′UTRor intron) of twootherwise unrelated
genes (DMPK and ZNF9). In muscle cells, RNAs from expanded
alleles of either repeat are able to bind and sequester alternative
splicing factors (muscleblind and CUG-BP) and in so doing, per-
turb the splicingpathways of proteins forwhich alternative splicing
is a necessary step for their complete range of functions (Mankodi
et al., 2002; Ranum and Day, 2004). It is now generally accepted
that RNA is the common pathogenic agent in these diseases most
likely through its impact on alternative splicing, although this
has recently been challenged with evidence that GSK3β mediates
at least some aspects of the RNA-based pathology in myotonic
dystrophy (Jones et al., 2012) and in a Drosophila model (van Eyk
et al., 2011).
Evidence for a more widespread role for RNA in neurodegener-
ative diseases has been steadily accumulating. SCA31 and SCA36
are due to large expansions of de novo 5 bp TGGAA repeat and an
existing 6 bp GGCCTG repeat, respectively – both located within
introns of different genes (Sato et al., 2009; Kobayashi et al., 2011).
An expanded GGGGCC repeat has recently been found to cause a
substantial proportion of cases of ALS and frontotemporal lobar
dementia (FTLD; DeJesus-Hernandez et al., 2011; Renton et al.,
2011). As indicated by others (Orr, 2011) “The location of this
repeat within an intron of the C9ORF72 gene along with some
evidence for alternative splicing of C9ORF72 transcripts brings
in to play a prominent aspect of non-coding repeat expansion
disorders – the role of RNA metabolism in pathogenesis.”
REPEAT ASSOCIATED NON-AUG TRANSLATION
The hairpin structure of expanded repeat RNA is such that it can
enable the initiation of translation in the absence of the normal
requirement of an AUG start codon (Zu et al., 2011). Although
this mechanism involves conversion of the RNA into peptides,
thereby rendering the RNA no longer “untranslated,” the phe-
nomenon can occur to RNA sequences that do not normally
appear in protein-coding sequences, i.e., RNA from introns or
5′ or 3′ untranslated regions of mRNAs. The resultant translated
FIGURE 2 | Competing hypotheses of expanded repeat disease
pathogenic pathways involving RNA. (1) RNA sequestration – via
alternative splicing (Mankodi et al., 2002; Ranum and Day, 2004) or
Akt/GSK3β pathway (van Eyk et al., 2011; Jones et al., 2012; Lawlor et al.,
2012). (2) RAN (repeat associated non-AUG) Translation (Zu et al., 2011;
Ash et al., 2013; Mori et al., 2013; Todd et al., 2013). (3)Toll “self”
RNA recognition (Lawlor et al., 2011; Yu et al., 2011; Samaraweera et al.,
(2013)).
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polypeptides can initiate from within the repeat sequence and in
any reading frame, therefore, a single strand containing repeat
RNA sequence can encode three different polypeptide sequences.
Since expanded repeat sequences are typically located in regions of
bi-directional transcription (Batra et al., 2010), the resultant tran-
scripts from both strands potentially enable the production of six
different peptide sequences, any of which may be toxic to the cell.
Such polypeptides have nowbeen detected in pathology specimens
from individuals affected with a number of different expanded
repeat diseases including DM1, fragile X syndrome (FRAXA) and
ALS/FTLD (Zu et al., 2011; Ash et al., 2013; Mori et al., 2013; Todd
et al., 2013). Of particular note, two recent publications (Ash et al.,
2013; Mori et al., 2013) have identiﬁed repeat associated non-AUG
(RAN)-translation of the GGGGCC expanded repeats that cause
ALS/FTLD into polypeptides that also form aggregates in affected
tissues. However, these aggregates are conﬁned to nerve cells and
are absent from adjacent glial cells that are also involved in the
pathology. On the other hand, the absence of visible aggregates
does not prove the absence of toxic peptides.
These RAN translation results have suggested that an aggre-
gate polypeptide analogous to polyglutamine could be neurotoxic
in diseases where the causative repeat expansion cannot encode
polyglutamine. However, this is doubtful in the cases of ALS and
FTLD because of the observations that mutations in either of two
RNA-binding proteins, FUS and TDP-43, can also cause disease
(Rutherford et al., 2008; Van Langenhove et al., 2010). In individu-
als affected due to these mutations, no such expanded polyGly-Pro
polypeptide is evident, therefore while polyGly-Pro may lead to
subtle differences in pathology (Ash et al., 2013; Mori et al., 2013),
it appears to play a modifying role at most.
Furthermore, inhibition of an RNA lariat debranching enzyme
has recently been shown to suppress TDP-43 toxicity in ALS dis-
ease models (Armakola et al., 2012). These observations reinforce
the view that RNA has a central role to play in this disease. While
the role of such polypeptides in disease pathogenesis is unclear,
for example, whether their aggregation may actually be protec-
tive rather than pernicious, they are a curious set of products
driven by the unusual structure of expanded repeat RNAs. One
possibility is that rather than the homopolymeric polypeptides
themselves being toxic, the initiation of translation within the
repeats could give rise to N-terminal truncated proteins devoid
of upstream functional domains that could then act as domi-
nant negative competitors for the full-length functionally intact
proteins.
DOUBLE-STRANDED EXPANDED REPEAT RNA IS PATHOGENIC
Drosophila models of expanded repeat diseases have been
described that speciﬁcally investigate the intrinsic toxicity of both
translated and untranslated expanded repeat sequences (Lawlor
et al., 2011; van Eyk et al., 2011, 2012; Samaraweera et al., 2013).
In one study (Lawlor et al., 2011), a single line of Drosophila
expressing untranslated CAG was identiﬁed with a marked degen-
erative phenotype (whereas multiple other random insertion lines
of the same transgene had no such phenotype). Upon detailed
characterization, this degenerative phenotype line was found to
have the repeat transgene inserted into an endogenous gene
(cheerio) in the opposite orientation to normal transcription.
Transcripts containing expanded repeats would, therefore, orig-
inate from both strands via bi-directional transcription. This
ﬁnding coincided with numerous reports in the literature that
expanded repeat disease loci are typically transcribed from both
DNA strands (see Batra et al., 2010). Therefore, this Drosophila
line mimicked a previously uncharacterized property of these
disease genes. Bi-directional transcription was subsequently mod-
eled in a controlled manner by co-expression from two different
transgenes of expanded rCAG∼100 together with rCUG∼100 [giv-
ing rise to rCAG.rCUG∼100 or double-strand RNA (dsRNA)]
to produce repeat-containing dsRNA (Lawlor et al., 2011). Flies
expressing dsRNA showed Dicer-dependent toxicity. Addition-
ally dsRNA expression throughout the nervous system caused
an age-dependent neurodegenerative phenotype. An abundance
of r(CAG)7 also implicated speciﬁc Dicer processing of the
rCAG.rCUG∼100 dsRNA as a pathogenic pathway in this model
(Lawlor et al., 2011). Similar ﬁndings have also been reported
in an independent Drosophila model (Yu et al., 2011). There are,
with all animal models, caveats. In order to manifest a phenotype
in the time frame of laboratory experiments, these Drosophila
(and other animal) models employ copy numbers well in excess
of those that cause pathology (after several decades) in some of
these diseases. This is thought to be due to an inverse relation-
ship between repeat copy number and age-at-onset, the basis of
which could be somatic repeat instability over time (see Figure 2
in Richards, 2001 and Swami et al., 2009). Furthermore, the
level of expression of the repeat RNAs required to give an early
phenotype in animal models (Lawlor et al., 2011; Yu et al., 2011)
may be well in excess of that of the endogenous human disease
gene. Importantly, however, examination of HD patient samples
(Bañez-Coronel et al., 2012) revealed the presence of the same
r(CAG)7 cleavage product seen in the Drosophila models, pro-
viding evidence in support of the activity of this pathway in HD
pathogenesis.
In an effort to identify further components of expanded
repeat RNA pathogenesis in Drosophila, microarray analyses of
Drosophila expressing rCAG.rCUG∼100 dsRNA have been under-
taken (Samaraweera et al., 2013). Changes in transcription proﬁles
revealed candidate pathways for mediating the resultant patho-
genesis. Alterations in transcripts common to several pathways
were detected, including components of inﬂammation and innate
immunity. Hallmarks of immune activation, including elevated
plasma tumor necrosis factor (TNF), appear prior to clinical
symptoms of dominantly inherited expanded repeat human dis-
eases (Moreau et al., 2005; Björkqvist et al., 2008). Therefore, the
Drosophila model expressing rCAG.rCUG∼100 dsRNA was utilized
to test two key elements of immune activation – the Toll and
autophagy pathways for their contribution to expanded repeat
RNA pathogenesis. Toll signaling pathway was identiﬁed as essen-
tial for dsRNA pathogenesis and autophagy was found to reduce
toxicity in this model (Samaraweera et al., 2013). Furthermore,
multiple reports implicate glial cells in the pathology of expanded
repeat diseases. Neurons are dependent upon glial cell function
that includes the destruction and removal of the carcasses of dead
neurons. The rCAG.rCUG∼100 dsRNA was found to impact nerve
cell function even when exclusively expressed in glial cells (Sama-
raweera et al., 2013), providing evidence that dsRNA pathology in
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Drosophila is, like the human expanded repeat diseases, non-cell
autonomous (Ilieva et al., 2009; Furrer et al., 2011).
The requirement for Toll signaling pathway in this Drosophila
model is intriguing. Toll-like receptors (TLRs) function in nor-
mal biology to protect an organism from infection by viruses and
bacteria. They recognize foreign pathogen molecules including
DNA and RNA through speciﬁc receptors (such as endosomal
TLR3) and can distinguish these nucleic acids (as “non-self”)
from the endogenous nucleic acids (“self”). Therefore, while the
rCAG.rCUG∼100 dsRNA is being expressed endogenously in this
Drosophila model, it is being recognized by theToll signaling path-
way as foreign or “non-self” – a recognition that then activates
innate inﬂammatory regulatory pathways, ultimately leading to
cell death.
PATHOGENIC MUTATIONS IN PROTEINS THAT
FUNCTIONALLY INTERACT WITH RNA
While it can be difﬁcult to ascribe speciﬁc functions to RNA in
pathogenic pathways, there are some noteworthy instances of
disease-causing mutations in proteins that functionally interact
with RNAs. By implication, the RNAs that these proteins normally
act upon are, therefore, likely contributors to and/or mediators of
the relevant pathogenic process.
RNA-BINDING MOTIFS – THE RNAS THAT HAVE THEM AND THE
PROTEINS THAT RECOGNIZE THEM
Recent discoveries regarding the importance of RNA–protein
recognition in disease pathogenesis have led to a renewed inter-
est in the role that these interactions play in biological processes.
While they have long been recognized as key regulators of gene
expression, only a small fraction have been functionally charac-
terized. A recent compendium of RNA-binding motifs (Ray et al.,
2013) highlighted both the signiﬁcance and scope of these interac-
tions. The human genome encodes at least 400 knownor predicted
RNA-binding proteins with a diverse array of RNA sequence-
binding motifs. Indeed the number of such human RNA-binding
proteins appears to be much higher than this, with 860 identiﬁed
in HeLa cells alone (Castello et al., 2012). The scope and speciﬁcity
of RNA recognition is determined both by the number and vari-
ety of RNA-binding proteins and by the number and variety of
RNA-sequence motifs that they bind.
FRAGILE X SYNDROME IS DUE TO LOSS OF RNA-BINDING PROTEIN
FUNCTION
Fragile X syndrome is a striking example of the role of an RNA-
binding protein in human disease. FRAXA is due to the expanded
CGG repeat that is responsible for the FRAXA rare, folate-sensitive
chromosomal fragile site (Kremer et al., 1991), located in the
5′UTR of the FMR1 gene (Verkerk et al., 1991). Expansion of the
repeat beyond ∼230 copies results in inactivation of the gene and
consequent loss of encoded FMRP (fragile X mental retardation
protein) function (Pieretti et al., 1991). The FMRP is an RNA-
binding protein with KH- and RGG-binding motifs (Ashley et al.,
1993). The loss of function of this protein is responsible for the
clinical symptoms as rare cases of point mutation or deletion of
the FMR1 gene have similar clinical symptoms. Indeed one of
these pathogenic point mutations is at a highly conserved amino
acid in a KH domain of FMRP highlighting the signiﬁcance of
the role of RNA interaction in FMRP function (De Boulle et al.,
1993). The FMRP has an impact on the translation of the mRNAs
with which it interacts (Darnell et al., 2001) and, therefore, its
absence leads to the dysregulation of the translation of these spe-
ciﬁc mRNAs. This is thought to be the proximal cause of the
symptoms of FRAXA.
THE INTRIGUING PATHOGENESIS OF AICARDI–GOUTIÈRES SYNDROME
Aicardi–Goutières syndrome (AGS) is a genetically heterogeneous
disorder that is due (at least in a substantial proportion of cases)
to the mutation of various nucleic acid-metabolizing enzymes,
including various subunits of ribonuclease H2 or the RNA-editing
enzyme ADAR1 (see Crow and Rehwinkel, 2009 and OMIM
#225750). AGS is characterized, in its more severe forms, by severe
neurological dysfunction in infancy that includes progressive
microcephaly, spasticity, dystonic posturing, profound psychomo-
tor retardation, and often death in early childhood (OMIM
#225750) (Figure 3). In its milder forms, these neurological
symptoms are diminished or even absent, but peripheral symp-
toms outside the nervous system are common to the phenotypic
spectrum and include thrombocytopenia, hepatosplenomegaly,
and elevated hepatic transaminases along with intermittent fever.
Chilblains are also a typical feature. Together these symptoms
demonstrate phenotypic overlap both with systemic lupus ery-
thematosus and with the sequelae of congenital infection (Crow
and Rehwinkel, 2009). The disease, therefore, appears to be due to
defects in the processes that remove and/or modify endogenous
nucleic acids. These endogenous unmodiﬁed nucleic acids then
accumulate and are sensed as “non-self” by TLRs, that, in turn,
activate innate inﬂammatory regulatory pathways. This bears a
striking resemblance to mechanisms we have identiﬁed as respon-
sible for dsRNApathogenesis in theDrosophila model of expanded
repeat neurodegenerative diseases.
HYPOTHESIS
EXPANDED REPEAT RNAS AS PATHOGENIC AGENTS BY TOLL “SELF”
RNA RECOGNITION
Repeat RNA sequences represent a pivotal point of potential weak-
ness in processes that utilize RNA–protein recognition, as the
repeat RNA sequence will harbor either a paucity or excess of
sequence-binding motifs. Expansion of repeat RNA sequences,
therefore, clearly has the potential to give rise to too much or too
little of an interaction that is a rate-limiting factor in a crucial bio-
logical process. RNA modiﬁcation is one process that is sequence
motif-dependent and known to be key to the distinction between
“self” and “non-self” by components of the innate immune path-
ways. Indeed, it has been shown that exogenous “non-self” RNAs
require in vitro modiﬁcation in order to escape innate immune
recognition and activation when transferred in vivo (Warren et al.,
2007; Pan, 2013). The exposure of the innate immune activators to
unmodiﬁed nucleic acids, including RNA, appears to be the prox-
imal cause of AGS. We, therefore, hypothesize that this provides
a clear molecular mechanism for the ability of expanded repeat
RNA sequences, through their paucity of RNA modiﬁcation, to
initiate pathogenesis in the dominantly inherited, expanded repeat
neurodegenerative diseases (Figure 4).
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FIGURE 3 | Pathogenic mutations in Aicardi–Goutières syndrome.
Mutations in genes in at least six distinct loci are able give rise to the
constellation of symptoms that deﬁnes Aicardi–Goutières syndrome. Four
of these (AGS2, AGS3, AGS4, and AGS6) are in genes that encode
RNA-metabolizing proteins. The remaining two that have been identiﬁed
(AGS1 and AGS5) are also in enzymes that have roles in nucleic acid
metabolism. Deﬁciencies in any one of these enzymes are thought to result
in the accumulation of endogenous nucleic acids that are sensed as
“non-self” byToll -like receptors, that in turn activate innate inﬂammatory
pathways (Crow and Rehwinkel, 2009).
FIGURE 4 | Hypothesis: expanded repeat neurodegenerative diseases are
caused by theTLR recognition (and resultant innate inflammatory
response) of repeat RNA as “non-self” due to their paucity of “self”
modification that is exposed upon Dicer processing of double-strand
RNA. Open circles represent sequence motifs for RNA modifying proteins;
ﬁlled circles represent the modiﬁcation of RNA at these speciﬁc sequence
motifs (e.g., by methylation or A > I editing). Dicer is required for pathology in
the Drosophila model and cleaves long high copy number repeat RNA down
to 21mers [mainly r(CAG)7 mers; Lawlor et al., 2011]. These r(CAG)7 mers are,
therefore, unmodiﬁed and recognized byTLRs as “non-self.”Toll -like receptor
pathways (most probably the endosomal TLR3 receptor) are required for
pathology (Samaraweera et al., 2013), through activation of the innate
inﬂammatory pathway. Autophagy reduces pathology, possibly by
metabolizing r(CAG)7 mers.
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ACTIVITY OF TOLL “SELF” RNA RECOGNITION IN
NEURODEGENERATIVE DISEASES
Double strand expanded repeat RNA pathology has been modeled
in Drosophila. What evidence is there that this pathway of TLR
recognition of expanded repeat RNA and subsequent activation
of the innate inﬂammatory cascade is active in the human dom-
inantly inherited neurodegenerative diseases due to expansion of
repeat sequences?
One of the key steps in dsRNA pathology is the generation
of r(CAG)7 21mers from the much greater copy number dou-
ble strand repeat RNA by Dicer. This r(CAG)7 21mer has been
identiﬁed in the brain RNA of individuals affected with HD
(Bañez-Coronel et al., 2012). The activity of Dicer is crucial to
the observed pathology in the Drosophila model (Lawlor et al.,
2011) and, therefore, it would appear that this step is a likely
proximal event in the observed phenotype. The appearance of
r(CAG)7 21mers in HD brain is therefore an important “molecu-
lar hallmark” of this pathway and a key indicator of its activity
in the human disease. Another, albeit less direct, indicator of
this pathway is seen in the increased activity of components of
the innate inﬂammatory response mechanism in human diseases
associated with expanded repeats. Elevated TNF is seen in the
Drosophila model as one read-out of innate immune activation
(Samaraweera et al., 2013) and both TNF and various interleukins
(i.e., IL-4, IL-5, IL-6, IL-8, and IL-10) have been found to be ele-
vated in people affected with the repeat expansion responsible for
HD even before clinical manifestation of the disease (Björkqvist
et al., 2008). Another indicator of innate immune activation in
HD is the abnormal peripheral chemokine proﬁle that has been
observed inHD (Wild et al., 2011). Various reports indicate activa-
tion of innate adaptive immunity via TLR signaling inALS (Casula
et al., 2011; Sta et al., 2011) – a disease that has recently been found,
at least in a proportion of instances, to be also due to an expanded
repeat (DeJesus-Hernandez et al., 2011; Renton et al., 2011).
CONCLUSION
A growing body of literature indicates a consistent asso-
ciation between innate immunity, neuroinﬂammation and
neurodegeneration (Shastri et al., 2013). Where there are exoge-
nous causes (e.g., trauma or infection), activation of the TLR
pathway can be attributed to an external agent (e.g., bacterial
lipopolysaccharide or viral RNA); however, a causal basis for
this relationship has not been clear when there is an endoge-
nous basis to the disease, e.g., expansion of a repeat sequence
beyond a pathogenic threshold. Recognition by the Toll receptor
pathway of expanded repeat RNA as “non-self” and consequent
activation of the innate immune inﬂammatory cascade pro-
vides a mechanism and a common pathogenic pathway for the
neurodegenerative diseases due to expanded repeats. This new
understanding, once proven in the relevant human diseases, will
provide new targets for intervention and ultimately, we hope, ther-
apeutic targets for drugs to delay onset and/or alleviate disease
progression.
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